BMS wins 'breakthrough' status for daclatasvir/asunaprevir dual regimen in HCV
This article was originally published in Scrip
Executive Summary
The FDA has granted breakthrough therapy designation to Bristol-Myers Squibb‘s dual regimen of daclatasvir and asunaprevir as a treatment for patients with genotype 1b chronic hepatitis C infection.